Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Solid Biosciences (SLDB) EBT: 2016-2024

Historic EBT for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to -$120.6 million.

  • Solid Biosciences' EBT fell 84.64% to -$38.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$120.6 million, marking a year-over-year decrease of 24.19%. This contributed to the annual value of -$120.6 million for FY2024, which is 24.19% down from last year.
  • Per Solid Biosciences' latest filing, its EBT stood at -$120.6 million for FY2024, which was down 24.19% from -$97.1 million recorded in FY2023.
  • Solid Biosciences' 5-year EBT high stood at -$72.2 million for FY2021, and its period low was -$120.6 million during FY2024.
  • In the last 3 years, Solid Biosciences' EBT had a median value of -$103.8 million in 2022 and averaged -$107.2 million.
  • As far as peak fluctuations go, Solid Biosciences' EBT climbed by 25.01% in 2020, and later plummeted by 43.84% in 2022.
  • Yearly analysis of 5 years shows Solid Biosciences' EBT stood at -$88.3 million in 2020, then rose by 18.24% to -$72.2 million in 2021, then plummeted by 43.84% to -$103.8 million in 2022, then increased by 6.48% to -$97.1 million in 2023, then fell by 24.19% to -$120.6 million in 2024.